manidipine has been researched along with Hypertension in 101 studies
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This present study assessed the antihypertensive efficacy of the fixed combination of manidipine and delapril by ambulatory blood pressure monitoring in patients with hypertension inadequately controlled by monotherapy with either component." | 10.21 | Fixed combination of manidipine and delapril in the treatment of mild to moderate essential hypertension: evaluation by 24-hour ambulatory blood pressure monitoring. ( Celentano, A; Fogari, R; Mugellini, A; Scanferla, F; Vaccarella, A; Zoppi, A, 2005) |
| "To compare the effect of manidipine 20 mg plus rosuvastatin 10 mg versus olmesartan 20 mg plus rosuvastatin 10 mg on markers of insulin resistance in patients with mixed dyslipidemia, hypertension, and impaired fasting glucose (IFG)." | 9.17 | Effects of manidipine plus rosuvastatin versus olmesartan plus rosuvastatin on markers of insulin resistance in patients with impaired fasting glucose, hypertension, and mixed dyslipidemia. ( Barkas, F; Elisaf, MS; Liamis, G; Liberopoulos, EN; Moutzouri, E; Rizos, CV, 2013) |
| "In accordance with experimental data after antihypertensive treatment of 4 weeks, intraglomerular pressure was significantly lower with the CCB manidipine than with amlodipine, resulting and explaining their disparate effects on albuminuria." | 9.17 | Effects of manidipine vs. amlodipine on intrarenal haemodynamics in patients with arterial hypertension. ( Alberici, M; Ott, C; Raff, U; Ritt, M; Schmieder, RE; Schneider, MP; Striepe, K, 2013) |
| " The objective of this study (the MARCADOR study) was to compare the effects of manidipine 20 mg with the extemporary combination of manidipine 10 mg/lisinopril 10 mg, amlodipine 10 mg and telmisartan 80 mg on insulin sensitivity, as well as metabolic, inflammatory and prothrombotic markers, in hypertensive non-diabetic patients with metabolic syndrome." | 9.15 | Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study. ( Comi-Diaz, C; Macias-Batista, A; Martinez-Martin, FJ; Pedrianes-Martin, P; Rodriguez-Rosas, H; Soriano-Perera, P, 2011) |
| "To evaluate the effects of manidipine versus amlodipine on blood pressure, albuminuria, insulin sensitivity, adiponectin, TNF-alpha and C-reactive protein in nondiabetic subjects with metabolic syndrome (ATP-III definition), including impaired fasting glucose (>5." | 9.14 | Manidipine in hypertensive patients with metabolic syndrome: the MARIMBA study. ( Martínez Martín, FJ, 2009) |
| "Patients with type 2 diabetes, mild-to-moderate hypertension (diastolic blood pressure 85-105 mmHg, systolic blood pressure <160 mmHg, and 24-hour mean systolic blood pressure >130 mmHg), and microalbuminuria were randomized to 1 year of doubleblind treatment with fixed-dose manidipine/delapril (n=54) or losartan/hydrochlorothiazide (HCTZ) (n=56)." | 9.14 | Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria. ( Fogari, R; Kohlmann, O; Laurent, S; Roca-Cusachs, A; Schmieder, RE; Wenzel, RR, 2009) |
| "The aim of this study was to compare the efficacy and safety of adding manidipine 20 mg versus amlodipine 10 mg to the treatment of diabetic patients with uncontrolled hypertension and microalbuminuria despite full-dose treatment with a renin-angiotensin system blocker for at least 6 months." | 9.13 | Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study. ( Martinez-Martin, FJ; Saiz-Satjes, M, 2008) |
| "To compare the effect of delapril/manidipine vs olmesartan/hydrochlorothiazide (HCTZ) combination on insulin sensitivity and plasma fibrinogen in obese hypertensive patients." | 9.13 | Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2008) |
| "The study demonstrated that the combination of manidipine and delapril is as effective as losartan and hydrochlorothiazide in treatment of hypertension in type 2 diabetes." | 9.13 | Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes. ( Fogari, R; Kohlmann, O; Laurent, S; Roca-Cusachs, A; Schmieder, RE; Triposkiadis, F; Wenzel, RR, 2008) |
| "We sought to compare the effect of manidipine versus hydrochlorothiazide (HCTZ) in addition to candesartan on the urinary albumin excretion rate (UAER) in hypertensive patients with type II diabetes and microalbuminuria." | 9.12 | Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. ( Corradi, L; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2007) |
| "The present study was undertaken to evaluate the effect on the development of ankle edema of adding the ACEI delapril to the CCB manidipine in patients with mild to moderate essential hypertension." | 9.12 | Effect on the development of ankle edema of adding delapril to manidipine in patients with mild to moderate essential hypertension: a three-way crossover study. ( Fogari, E; Fogari, R; Malamani, G; Mugellini, A; Perrone, T; Rinaldi, A; Zoppi, A, 2007) |
| "The aim of this study was to compare the antihypertensive efficacy, tolerability, and effect on metabolic risk factors of manidipine, a new dihydropyridine calcium channel antagonist, and enalapril, a widely used angiotensin-converting enzyme inhibitor, in patients with mild to moderate essential hypertension and type 2 diabetes." | 9.11 | Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study. ( Luque Otero, M; Martell Claros, N, 2005) |
| "To demonstrate that calcium channel blockers can improve insulin resistance clinically, we investigated the effects of the calcium channel blockers, amlodipine, manidipine and cilnidipine on serum levels of steroid hormones and insulin." | 9.11 | Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients. ( Miyachi, Y; Ueshiba, H, 2004) |
| "This study was done to evaluate the effect of treatment with manidipine as compared with atenolol on thrombin-mediated platelet aggregation in elderly patients with isolated systolic hypertension and type II diabetes mellitus." | 9.11 | Effect of manidipine as compared to atenolol on platelet aggregation in elderly patients with isolated systolic hypertension and type II diabetes mellitus. ( Corradi, L; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Rinaldi, A; Zoppi, A, 2005) |
| "The aim of this open-labelled, randomised, parallel-group study was to evaluate the effect of long-term monotherapy with manidipine or lisinopril on albumin excretion rate (AER) and left ventricular mass index (LVMI) in hypertensive patients with type-2 diabetes and microalbuminuria." | 9.11 | Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. ( Destro, M; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2005) |
| "The results of this study suggest that delapril alone or combined with manidipine is well tolerated and as effective as enalapril alone or combined with HCTZ in lowering blood pressure in patients with mild to moderate essential hypertension." | 9.11 | Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension: results of a randomized trial. ( Cremonesi, G; Dobovisek, J; Fogari, R; Mugellini, A; Planinc, D, 2004) |
| "Candesartan, an AT(1) receptor antagonist, has been reported to have no association with persistent cough in subjects with hypertension, but there has been no study on the safety of its administration to hypertensive patients with symptomatic asthma." | 9.09 | Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma. ( Abe, S; Hashimoto, M; Oashi, K; Saikai, T; Suzuki, K; Tanaka, H; Tanaka, S; Teramoto, S, 2001) |
| "To evaluate the efficacy, metabolic effects and tolerability of manidipine used in the treatment of stage I and II essential hypertensive patients with overweight or android obesity." | 9.09 | [Manidipine in the treatment of stage I and II essential hypertension patients with overweight or android obesity. A Brazilian multicentre study of efficacy, tolerability and metabolic effects]. ( Kohlmann, O; Ribeiro, AB, 2001) |
| "This double-blind, multicenter trial compared antihypertensive efficacy, tolerability, and impact on quality of life of manidipine and amlodipine in patients with mild-to-moderate essential hypertension." | 9.09 | Efficacy, tolerability, and impact on quality of life of long-term treatment with manidipine or amlodipine in patients with essential hypertension. ( De Cesaris, R; La Commare, P; Omboni, S; Palatini, P; Zanchetti, A, 2001) |
| "In a double-blind, randomized, placebo-controlled, parallel-group study the ambulatory blood pressure monitoring (ABPM) and relative tolerability of different doses of manidipine hydrochloride (10, 20 and 40 mg) were compared to placebo in patients with mild to moderate essential hypertension." | 9.08 | Evaluation by 24-hour ambulatory blood pressure monitoring of efficacy of manidipine hydrochloride 10, 20 or 40 mg once daily as compared to placebo in treating mild to moderate essential hypertension: a double-blind, randomized, parallel group, placebo-c ( Fogari, R; Lusardi, P; Mugellini, A; Poletti, L; Preti, P; Zoppi, A, 1996) |
| "The aim of this multicenter study was to evaluate the efficacy and tolerability of manidipine hydrochloride, a new calcium-antagonist of the dihydropyridine group, in the long-term treatment of mild to moderate hypertension." | 9.08 | Efficacy and tolerability of manidipine hydrochloride in the long-term treatment of mild-moderate hypertension. Manidipine Efficacy in Long-Term Treatment Group. ( Fogari, R; Lusardi, P; Mugellini, A; Zoppi, A, 1996) |
| "The 24-h blood pressure (BP) response to once-daily manidipine monotherapy was examined in an open, nonrandomized study of 17 patients with untreated essential hypertension." | 9.07 | Efficacy of manidipine on circadian blood pressure in essential hypertension. ( Honma, H; Ishii, H; Kohno, I; Nakamura, T; Tamura, K; Tsuruta, I, 1992) |
| "In order to investigate the effects of manidipine, a newly developed long-acting calcium antagonist, on the diurnal variation of arterial pressure and systemic hemodynamics in patients with essential hypertension, we examined 24-h arterial pressure using a direct arterial pressure monitoring method and cardiac output using the cuvette method before and during manidipine treatment." | 9.07 | A study of the effects of manidipine on the diurnal variation of arterial pressure and hemodynamics in patients with essential hypertension. ( Ishii, M; Iwata, A; Kawano, Y; Minamisawa, K; Miyakawa, Y; Tochikubo, O, 1992) |
| "The effects of manidipine (10 mg/day for 7 days) on the renal hemodynamics and vasoactive humoral factors were examined in 6 adults with diabetes mellitus (DM)." | 9.07 | Effects of a new calcium antagonist, manidipine, on the renal hemodynamics and the vasoactive humoral factors in patients with diabetes mellitus. ( Fujishima, M; Fujita, S; Hirakata, H; Iino, K; Ishida, I; Kashiwagi, M; Okuda, S; Yoshinari, M, 1992) |
| "The effect of manidipine, a new Ca2+ antagonist, on intrarenal hemodynamics was assessed in essential hypertension and compared with nicardipine, a previously studied Ca2+ antagonist." | 9.07 | Effect of manidipine, a new calcium antagonist, on intrarenal hemodynamics in essential hypertension. ( Abe, H; Ashida, T; Imanishi, M; Kawano, Y; Kimura, G; Kojima, S; Murakami, K; Sanai, T; Yoshida, K; Yoshimi, H, 1992) |
| " The aim of this study was to compare the effects of adding manidipine to the treatment of patients with essential hypertension and persistent albuminuria, despite full-dose treatment with a renin-angiotensin system blocker on urinary albumin excretion (UAE) after 24 weeks of therapy." | 8.86 | Manidipine treatment in patients with albuminuria not sufficiently reduced with renin-angiotensin system blockers. ( Felip, A; Galceran, J; Plana, J; Pou, G; Sobrino, J; Vila, J, 2010) |
| "Manidipine has shown antihypertensive efficacy and appears to be well tolerated in adult and elderly patients with mild or moderate essential hypertension." | 8.81 | Manidipine: a review of its use in hypertension. ( Cheer, SM; McClellan, K, 2001) |
| "The open trial was designed to evaluate the effects of long-term antihypertensive treatment with the calcium-channel blocker, manidipine and the angiotensin converting enzyme (ACE) inhibitor, delapril on insulin sensitivity in Japanese non-insulin dependent diabetes mellitus (NIDDM) patients with essential hypertension." | 7.69 | Effect of manidipine and delapril on insulin sensitivity in type 2 diabetic patients with essential hypertension. ( Akai, H; Hinokio, Y; Hirai, A; Hirai, M; Hirai, S; Kawasaki, H; Ohtomo, M; Onoda, M; Satoh, Y; Suzuki, S; Toyota, T, 1996) |
| "The effect of manidipine on cardiac hypertrophy, coronary circulation, left ventricular weight and maximal coronary flow in hypertension was measured in DOCA/salt treated systolic hypertensive rats with and without manidipine treatment." | 7.68 | Effect of manidipine on cardiac hypertrophy and coronary circulation in DOCA/salt hypertensive rats. ( Asayama, J; Itoh, H; Kuwabara, T; Nakagawa, M; Nakata, T; Sasaki, S; Takeda, K; Takesako, T; Tanabe, S; Yamahara, Y, 1992) |
| "The effect of a calcium antagonist, manidipine, on blood pressure and proteinuria induced by the inhibition of endothelial-derived relaxation factor (EDRF) formation was examined." | 7.68 | Preventive effect of manidipine on severe hypertension and proteinuria induced by the inhibition of endothelial-derived relaxation factor formation in stroke-prone spontaneously hypertensive rats. ( Ikeda, K; Nara, Y; Yamori, Y, 1992) |
| "Manidipine 10 mg/day was added, increasing to 20 mg/day if the target BP was not reached after 3 months' treatment." | 6.76 | Manidipine for hypertension not controlled by dual therapy in patients with diabetes mellitus: a non-comparative, open-label study. ( de la Cruz, JJ; Martell-Claros, N, 2011) |
| " Safety and tolerability evaluations were based on adverse events, ECG and laboratory tests, and clinically relevant reports of abnormalities." | 6.73 | Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study. ( Alberici, M; Lembo, G; Payeras, AC; Sladek, K, 2007) |
| "Manidipine plus delapril is a fixed-dose combination of a third-generation dihydropyridine calcium antagonist and an angiotensin-converting enzyme inhibitor, which is effective in mild-to-moderately hypertensive patients with an inadequate response to monotherapy." | 6.44 | Manidipine plus delapril in patients with Type 2 diabetes and hypertension: reducing cardiovascular risk and end-organ damage. ( Coca, A, 2007) |
| "Manidipine is a lipophilic, third-generation dihydropyridine calcium channel antagonist with a high degree of selectivity for the vasculature, thereby inducing marked peripheral vasodilation with negligible cardiodepression." | 6.42 | Manidipine: a review of its use in the management of hypertension. ( McKeage, K; Scott, LJ, 2004) |
| "This present study assessed the antihypertensive efficacy of the fixed combination of manidipine and delapril by ambulatory blood pressure monitoring in patients with hypertension inadequately controlled by monotherapy with either component." | 6.21 | Fixed combination of manidipine and delapril in the treatment of mild to moderate essential hypertension: evaluation by 24-hour ambulatory blood pressure monitoring. ( Celentano, A; Fogari, R; Mugellini, A; Scanferla, F; Vaccarella, A; Zoppi, A, 2005) |
| "Manidipine is a third-generation dihydropyridine calcium antagonist, which causes systemic vasodilation by inhibiting the voltage-dependent calcium inward currents in smooth muscle cells." | 5.32 | Role of manidipine in the management of patients with hypertension. ( Casiglia, E; Mazza, A; Pessina, AC; Tikhonoff, V, 2004) |
| "Manidipine-treated groups 3 to 5 had significantly less proteinuria than group 2." | 5.29 | Effects of a calcium antagonist, manidipine, on progressive renal injury associated with mild hypertension in remnant kidneys. ( Hishida, A; Kobayashi, S, 1995) |
| "In AMANDHA trial, the addition of manidipine, but not amlodipine, in diabetic patients with uncontrolled hypertension, microalbuminuria and preserved renal function resulted in a large decrease of urinary albumin excretion (UAE) despite similar blood pressure (BP) reductions." | 5.24 | Factors associated with the reduction of albumin excretion in diabetic hypertensive patients: differential effect of manidipine versus amlodipine. ( Martinez-Martin, FJ; Roca-Cusachs, A; Saiz-Satjes, M, 2017) |
| "In accordance with experimental data after antihypertensive treatment of 4 weeks, intraglomerular pressure was significantly lower with the CCB manidipine than with amlodipine, resulting and explaining their disparate effects on albuminuria." | 5.17 | Effects of manidipine vs. amlodipine on intrarenal haemodynamics in patients with arterial hypertension. ( Alberici, M; Ott, C; Raff, U; Ritt, M; Schmieder, RE; Schneider, MP; Striepe, K, 2013) |
| "To compare the effect of manidipine 20 mg plus rosuvastatin 10 mg versus olmesartan 20 mg plus rosuvastatin 10 mg on markers of insulin resistance in patients with mixed dyslipidemia, hypertension, and impaired fasting glucose (IFG)." | 5.17 | Effects of manidipine plus rosuvastatin versus olmesartan plus rosuvastatin on markers of insulin resistance in patients with impaired fasting glucose, hypertension, and mixed dyslipidemia. ( Barkas, F; Elisaf, MS; Liamis, G; Liberopoulos, EN; Moutzouri, E; Rizos, CV, 2013) |
| " The objective of this study (the MARCADOR study) was to compare the effects of manidipine 20 mg with the extemporary combination of manidipine 10 mg/lisinopril 10 mg, amlodipine 10 mg and telmisartan 80 mg on insulin sensitivity, as well as metabolic, inflammatory and prothrombotic markers, in hypertensive non-diabetic patients with metabolic syndrome." | 5.15 | Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study. ( Comi-Diaz, C; Macias-Batista, A; Martinez-Martin, FJ; Pedrianes-Martin, P; Rodriguez-Rosas, H; Soriano-Perera, P, 2011) |
| "Patients with type 2 diabetes, mild-to-moderate hypertension (diastolic blood pressure 85-105 mmHg, systolic blood pressure <160 mmHg, and 24-hour mean systolic blood pressure >130 mmHg), and microalbuminuria were randomized to 1 year of doubleblind treatment with fixed-dose manidipine/delapril (n=54) or losartan/hydrochlorothiazide (HCTZ) (n=56)." | 5.14 | Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria. ( Fogari, R; Kohlmann, O; Laurent, S; Roca-Cusachs, A; Schmieder, RE; Wenzel, RR, 2009) |
| "To evaluate the effects of manidipine versus amlodipine on blood pressure, albuminuria, insulin sensitivity, adiponectin, TNF-alpha and C-reactive protein in nondiabetic subjects with metabolic syndrome (ATP-III definition), including impaired fasting glucose (>5." | 5.14 | Manidipine in hypertensive patients with metabolic syndrome: the MARIMBA study. ( Martínez Martín, FJ, 2009) |
| "The aim of this study was to compare the efficacy and safety of adding manidipine 20 mg versus amlodipine 10 mg to the treatment of diabetic patients with uncontrolled hypertension and microalbuminuria despite full-dose treatment with a renin-angiotensin system blocker for at least 6 months." | 5.13 | Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study. ( Martinez-Martin, FJ; Saiz-Satjes, M, 2008) |
| "The study demonstrated that the combination of manidipine and delapril is as effective as losartan and hydrochlorothiazide in treatment of hypertension in type 2 diabetes." | 5.13 | Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes. ( Fogari, R; Kohlmann, O; Laurent, S; Roca-Cusachs, A; Schmieder, RE; Triposkiadis, F; Wenzel, RR, 2008) |
| "To compare the effect of delapril/manidipine vs olmesartan/hydrochlorothiazide (HCTZ) combination on insulin sensitivity and plasma fibrinogen in obese hypertensive patients." | 5.13 | Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2008) |
| "We sought to compare the effect of manidipine versus hydrochlorothiazide (HCTZ) in addition to candesartan on the urinary albumin excretion rate (UAER) in hypertensive patients with type II diabetes and microalbuminuria." | 5.12 | Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. ( Corradi, L; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2007) |
| "The present study was undertaken to evaluate the effect on the development of ankle edema of adding the ACEI delapril to the CCB manidipine in patients with mild to moderate essential hypertension." | 5.12 | Effect on the development of ankle edema of adding delapril to manidipine in patients with mild to moderate essential hypertension: a three-way crossover study. ( Fogari, E; Fogari, R; Malamani, G; Mugellini, A; Perrone, T; Rinaldi, A; Zoppi, A, 2007) |
| "The results of this study suggest that delapril alone or combined with manidipine is well tolerated and as effective as enalapril alone or combined with HCTZ in lowering blood pressure in patients with mild to moderate essential hypertension." | 5.11 | Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension: results of a randomized trial. ( Cremonesi, G; Dobovisek, J; Fogari, R; Mugellini, A; Planinc, D, 2004) |
| "The aim of this study was to compare the antihypertensive efficacy, tolerability, and effect on metabolic risk factors of manidipine, a new dihydropyridine calcium channel antagonist, and enalapril, a widely used angiotensin-converting enzyme inhibitor, in patients with mild to moderate essential hypertension and type 2 diabetes." | 5.11 | Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study. ( Luque Otero, M; Martell Claros, N, 2005) |
| "To demonstrate that calcium channel blockers can improve insulin resistance clinically, we investigated the effects of the calcium channel blockers, amlodipine, manidipine and cilnidipine on serum levels of steroid hormones and insulin." | 5.11 | Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients. ( Miyachi, Y; Ueshiba, H, 2004) |
| "The aim of this open-labelled, randomised, parallel-group study was to evaluate the effect of long-term monotherapy with manidipine or lisinopril on albumin excretion rate (AER) and left ventricular mass index (LVMI) in hypertensive patients with type-2 diabetes and microalbuminuria." | 5.11 | Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. ( Destro, M; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2005) |
| "This study was done to evaluate the effect of treatment with manidipine as compared with atenolol on thrombin-mediated platelet aggregation in elderly patients with isolated systolic hypertension and type II diabetes mellitus." | 5.11 | Effect of manidipine as compared to atenolol on platelet aggregation in elderly patients with isolated systolic hypertension and type II diabetes mellitus. ( Corradi, L; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Rinaldi, A; Zoppi, A, 2005) |
| "Candesartan, an AT(1) receptor antagonist, has been reported to have no association with persistent cough in subjects with hypertension, but there has been no study on the safety of its administration to hypertensive patients with symptomatic asthma." | 5.09 | Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma. ( Abe, S; Hashimoto, M; Oashi, K; Saikai, T; Suzuki, K; Tanaka, H; Tanaka, S; Teramoto, S, 2001) |
| "To evaluate the efficacy, metabolic effects and tolerability of manidipine used in the treatment of stage I and II essential hypertensive patients with overweight or android obesity." | 5.09 | [Manidipine in the treatment of stage I and II essential hypertension patients with overweight or android obesity. A Brazilian multicentre study of efficacy, tolerability and metabolic effects]. ( Kohlmann, O; Ribeiro, AB, 2001) |
| "This double-blind, multicenter trial compared antihypertensive efficacy, tolerability, and impact on quality of life of manidipine and amlodipine in patients with mild-to-moderate essential hypertension." | 5.09 | Efficacy, tolerability, and impact on quality of life of long-term treatment with manidipine or amlodipine in patients with essential hypertension. ( De Cesaris, R; La Commare, P; Omboni, S; Palatini, P; Zanchetti, A, 2001) |
| "Patients aged 60 years and older with essential hypertension were treated with an angiotensin-converting enzyme inhibitor (ACE-I), delapril (Adecut) or a long-acting calcium (Ca)-antagonist, manidipine (Calslot) for 3 years." | 5.09 | Practitioner's Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (The PATE-Hypertension Study) in Japan. ( Ogihara, T, 2000) |
| " We sought to assess the antihypertensive and metabolic effects of the new dihydropyridine calcium antagonist manidipine (M) in patients with diabetes mellitus and essential hypertension as compared with the ACE inhibitor enalapril (E)." | 5.09 | Antihypertensive efficacy of manidipine and enalapril in hypertensive diabetic patients. ( Agabiti-Rosei, E; Casati, R; Fogari, R; Leonetti, G; Mancia, G; Montemurro, G; Nami, R; Omboni, S; Pessina, AC; Pirrelli, A; Zanchetti, A, 2000) |
| "The aim of this study was to compare the chronic effects of four dihydropyridine calcium antagonists with different pharmacologic characteristics, amlodipine, felodipine, lacidipine and manidipine,on blood pressure (BP), heart rate (HR) and plasma norepinephrine (NE) levels in patients with mild to moderate essential hypertension." | 5.09 | Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension. ( Corradi, L; Fogari, R; Malalamani, GD; Mugellini, A; Preti, P; Zoppi, A, 2000) |
| "In a double-blind, randomized, placebo-controlled, parallel-group study the ambulatory blood pressure monitoring (ABPM) and relative tolerability of different doses of manidipine hydrochloride (10, 20 and 40 mg) were compared to placebo in patients with mild to moderate essential hypertension." | 5.08 | Evaluation by 24-hour ambulatory blood pressure monitoring of efficacy of manidipine hydrochloride 10, 20 or 40 mg once daily as compared to placebo in treating mild to moderate essential hypertension: a double-blind, randomized, parallel group, placebo-c ( Fogari, R; Lusardi, P; Mugellini, A; Poletti, L; Preti, P; Zoppi, A, 1996) |
| "The aim of this multicenter study was to evaluate the efficacy and tolerability of manidipine hydrochloride, a new calcium-antagonist of the dihydropyridine group, in the long-term treatment of mild to moderate hypertension." | 5.08 | Efficacy and tolerability of manidipine hydrochloride in the long-term treatment of mild-moderate hypertension. Manidipine Efficacy in Long-Term Treatment Group. ( Fogari, R; Lusardi, P; Mugellini, A; Zoppi, A, 1996) |
| "We investigated the relationship between cardiovascular autonomic nervous system function and carotid arterial distensibility during treatment with an angiotensin converting enzyme inhibitor (derapril) or a calcium channel blocker (manidipine) for hypertension." | 5.08 | Effects of an ACE inhibitor and a calcium channel blocker on cardiovascular autonomic nervous system and carotid distensibility in patients with mild to moderate hypertension. ( Doba, N; Ishikawa, Y; Kimura, Y; Morita, S; Saito, I; Sakuma, Y; Shiojima, K; Tomiyama, H; Yamamoto, A; Yoshida, H, 1998) |
| "The effects of manidipine (10 mg/day for 7 days) on the renal hemodynamics and vasoactive humoral factors were examined in 6 adults with diabetes mellitus (DM)." | 5.07 | Effects of a new calcium antagonist, manidipine, on the renal hemodynamics and the vasoactive humoral factors in patients with diabetes mellitus. ( Fujishima, M; Fujita, S; Hirakata, H; Iino, K; Ishida, I; Kashiwagi, M; Okuda, S; Yoshinari, M, 1992) |
| "The effect of manidipine, a new Ca2+ antagonist, on intrarenal hemodynamics was assessed in essential hypertension and compared with nicardipine, a previously studied Ca2+ antagonist." | 5.07 | Effect of manidipine, a new calcium antagonist, on intrarenal hemodynamics in essential hypertension. ( Abe, H; Ashida, T; Imanishi, M; Kawano, Y; Kimura, G; Kojima, S; Murakami, K; Sanai, T; Yoshida, K; Yoshimi, H, 1992) |
| "The effects of the calcium antagonist manidipine 20 mg/day on changes in blood pressure and renal hemodynamics in response to acute stress by the mental arithmetic test (MAT) and the cold pressor test (CPT) were investigated in 14 patients with essential hypertension (median age: 50 +/- 2, WHO stage I-II)." | 5.07 | The effect of manidipine on renal hemodynamics in essential hypertensive patients: responses to acute stress. ( Hara, K; Itou, S; Kawamura, H; Maki, M; Mitsubayashi, H; Suzuki, K; Usui, W; Yasugi, T, 1992) |
| "The 24-h blood pressure (BP) response to once-daily manidipine monotherapy was examined in an open, nonrandomized study of 17 patients with untreated essential hypertension." | 5.07 | Efficacy of manidipine on circadian blood pressure in essential hypertension. ( Honma, H; Ishii, H; Kohno, I; Nakamura, T; Tamura, K; Tsuruta, I, 1992) |
| "In order to investigate the effects of manidipine, a newly developed long-acting calcium antagonist, on the diurnal variation of arterial pressure and systemic hemodynamics in patients with essential hypertension, we examined 24-h arterial pressure using a direct arterial pressure monitoring method and cardiac output using the cuvette method before and during manidipine treatment." | 5.07 | A study of the effects of manidipine on the diurnal variation of arterial pressure and hemodynamics in patients with essential hypertension. ( Ishii, M; Iwata, A; Kawano, Y; Minamisawa, K; Miyakawa, Y; Tochikubo, O, 1992) |
| " The aim of this study was to compare the effects of adding manidipine to the treatment of patients with essential hypertension and persistent albuminuria, despite full-dose treatment with a renin-angiotensin system blocker on urinary albumin excretion (UAE) after 24 weeks of therapy." | 4.86 | Manidipine treatment in patients with albuminuria not sufficiently reduced with renin-angiotensin system blockers. ( Felip, A; Galceran, J; Plana, J; Pou, G; Sobrino, J; Vila, J, 2010) |
| "Manidipine is a lipophilic, third-generation, highly vasoselective, dihydropyridine (DHP) calcium channel antagonist, which, when given on a once-daily basis, effectively reduces blood pressure (BP) in patients with mild-to-moderate essential hypertension." | 4.82 | Antihypertensive effect of manidipine. ( Roca-Cusachs, A; Triposkiadis, F, 2005) |
| "Manidipine has shown antihypertensive efficacy and appears to be well tolerated in adult and elderly patients with mild or moderate essential hypertension." | 4.81 | Manidipine: a review of its use in hypertension. ( Cheer, SM; McClellan, K, 2001) |
| "Delapril/manidipine 30 mg/10 mg is a new oral, once-daily, fixed combination of an ACE inhibitor and a dihydropyridine calcium-channel antagonist for the treatment of essential hypertension." | 3.73 | Delapril/manidipine. ( Keating, GM; McCormack, PL, 2006) |
| "The open trial was designed to evaluate the effects of long-term antihypertensive treatment with the calcium-channel blocker, manidipine and the angiotensin converting enzyme (ACE) inhibitor, delapril on insulin sensitivity in Japanese non-insulin dependent diabetes mellitus (NIDDM) patients with essential hypertension." | 3.69 | Effect of manidipine and delapril on insulin sensitivity in type 2 diabetic patients with essential hypertension. ( Akai, H; Hinokio, Y; Hirai, A; Hirai, M; Hirai, S; Kawasaki, H; Ohtomo, M; Onoda, M; Satoh, Y; Suzuki, S; Toyota, T, 1996) |
| "The effect of a calcium antagonist, manidipine, on blood pressure and proteinuria induced by the inhibition of endothelial-derived relaxation factor (EDRF) formation was examined." | 3.68 | Preventive effect of manidipine on severe hypertension and proteinuria induced by the inhibition of endothelial-derived relaxation factor formation in stroke-prone spontaneously hypertensive rats. ( Ikeda, K; Nara, Y; Yamori, Y, 1992) |
| "The renal effects of manidipine hydrochloride were investigated in ten hospitalised patients with mild-to-moderate essential hypertension." | 3.68 | Renal effects of manidipine hydrochloride. A new calcium antagonist in hypertensive patients. ( Ise, T; Kobayashi, K; Ohta, H; Ohta, K; Sasaki, T; Satoh, S; Takabatake, T, 1993) |
| "Clinical studies were performed on patients with mild-to-moderate essential hypertension to elucidate the efficacy and mode of action of manidipine." | 3.68 | Efficacy and mode of action of manidipine: a new calcium antagonist. ( Iimura, O; Shimamoto, K, 1993) |
| "This study was designed to investigate the effects of antihypertensive drugs on vascular hypertrophy and vascular angiotensin II in vivo in spontaneously hypertensive rats (SHR)." | 3.68 | Regression of hypertension-induced vascular hypertrophy by an ACE inhibitor and calcium antagonist in the spontaneously hypertensive rat. ( Higaki, J; Mikami, H; Morishita, R; Nagano, M; Nakamura, F; Ogihara, T; Tomita, N; Yu, H, 1992) |
| "The effect of manidipine on cardiac hypertrophy, coronary circulation, left ventricular weight and maximal coronary flow in hypertension was measured in DOCA/salt treated systolic hypertensive rats with and without manidipine treatment." | 3.68 | Effect of manidipine on cardiac hypertrophy and coronary circulation in DOCA/salt hypertensive rats. ( Asayama, J; Itoh, H; Kuwabara, T; Nakagawa, M; Nakata, T; Sasaki, S; Takeda, K; Takesako, T; Tanabe, S; Yamahara, Y, 1992) |
| "Manidipine 10 mg/day was added, increasing to 20 mg/day if the target BP was not reached after 3 months' treatment." | 2.76 | Manidipine for hypertension not controlled by dual therapy in patients with diabetes mellitus: a non-comparative, open-label study. ( de la Cruz, JJ; Martell-Claros, N, 2011) |
| " Safety and tolerability evaluations were based on adverse events, ECG and laboratory tests, and clinically relevant reports of abnormalities." | 2.73 | Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study. ( Alberici, M; Lembo, G; Payeras, AC; Sladek, K, 2007) |
| "In hypertensive patients with type II diabetes mellitus, the combination delapril-manidipine may determine a greater improvement of the fibrinolytic function than the respective monotherapy, while the association irbesartan-hydrochlorothiazide may worsen it." | 2.71 | Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus. ( Corradi, L; Derosa, G; Fogari, E; Fogari, R; Mugellini, A; Preti, P; Zoppi, A, 2004) |
| " In addition, ABPM confirmed a consistent antihypertensive activity throughout the 24-hour dosing interval, without effect on the circadian BP profile." | 2.69 | Effect of low-dose manidipine on ambulatory blood pressure in very elderly hypertensives. ( Corradi, L; Fogari, R; Lusardi, P; Mugellini, A; Preti, P; Zoppi, A, 1999) |
| "Thirty-nine hypertensive patients with type 2 diabetes mellitus were followed under long-term treatment (mean, 20." | 2.69 | Delapril versus manidipine in hypertensive therapy to halt the type-2-diabetes-mellitus-associated nephropathy. ( Fujita, R; Hayashi, Y; Inoue, M; Iwamoto, Y; Kageyama, S; Kitamura, S; Makino, F; Okuda, Y; Shiba, T; Tada, H; Takahasi, C, 2000) |
| "In order to evaluate the antihypertensive effects of manidipine, at the dosage of 10 or 20 mg once daily, we studied 36 patients (12 males and 24 females, mean age 54." | 2.68 | Anti-hypertensive effect of manidipine: 24 hours monitoring evaluation and Doppler-echocardiographic remarks. ( Celentano, A; Cloro, C; Cosco, C; Crivaro, M; De Divitiis, O; Di Palma Esposito, N; Mattioli, PL; Oliviero, M; Palmieri, V; Perticone, F; Pietropaolo, I; Tammaro, P, 1996) |
| " No severe adverse effects were encountered during therapy." | 2.67 | Clinical evaluation of the efficacy and safety of manidipine in hypertensive patients with renal disorders. ( Fukuchi, S; Haga, H; Mizuno, K; Takahashi, M; Watanabe, Y, 1992) |
| "Manidipine treatment observed at a daily dose of 10 to 20 mg produced effective reduction in blood pressure during the course of the study." | 2.67 | Effect of manidipine, a novel calcium channel blocker, on quality of life in hypertensive patients. ( Higashimori, K; Ishikawa, H; Kagoshima, T; Mikami, H; Nagano, M; Nakagawa, M; Nonaka, H; Ogihara, T; Sasaki, S; Takeda, K, 1992) |
| " Head-to-head randomized controlled trials (RCTs) of 12 months minimum duration reporting comparative efficacy (changes in systolic and diastolic blood pressure) and safety (total adverse events and ankle oedema), were included." | 2.47 | Efficacy and safety profiles of manidipine compared with amlodipine: a meta-analysis of head-to-head trials. ( Laurent, S; Richy, FF, 2011) |
| "Manidipine plus delapril is a fixed-dose combination of a third-generation dihydropyridine calcium antagonist and an angiotensin-converting enzyme inhibitor, which is effective in mild-to-moderately hypertensive patients with an inadequate response to monotherapy." | 2.44 | Manidipine plus delapril in patients with Type 2 diabetes and hypertension: reducing cardiovascular risk and end-organ damage. ( Coca, A, 2007) |
| "Manidipine is a third-generation dihydropyridine (DHP) calcium channel antagonist that blocks both L and T-type calcium channels." | 2.43 | Renal protection in hypertensive patients: selection of antihypertensive therapy. ( Wenzel, RR, 2005) |
| "Manidipine is a lipophilic, third-generation dihydropyridine calcium channel antagonist with a high degree of selectivity for the vasculature, thereby inducing marked peripheral vasodilation with negligible cardiodepression." | 2.42 | Manidipine: a review of its use in the management of hypertension. ( McKeage, K; Scott, LJ, 2004) |
| " There were 8 cases of adverse effects before substitution and 4 after substitution." | 1.34 | [Evaluation of efficacy and safety of manidipine hydrochloride among essential hypertensive patients: Substitution from branded product (Calslot) to Generic Product (Manidip)]. ( Igari, Y; Imai, Y; Kobayashi, H; Obara, T; Ohkubo, T; Oikawa, T; Saito, S; Takahashi, M; Takahashi, N; Takahashi, T, 2007) |
| "Manidipine is a third-generation dihydropyridine calcium antagonist, which causes systemic vasodilation by inhibiting the voltage-dependent calcium inward currents in smooth muscle cells." | 1.32 | Role of manidipine in the management of patients with hypertension. ( Casiglia, E; Mazza, A; Pessina, AC; Tikhonoff, V, 2004) |
| "This may represent an advantage in the treatment of hypertension with risk of brain damage." | 1.31 | Hypertensive brain damage: comparative evaluation of protective effect of treatment with dihydropyridine derivatives in spontaneously hypertensive rats. ( Amenta, F; Sabbatini, M; Tomassoni, D, 2001) |
| "Hypertension is the main cause of stroke that represents the second most common cause of death in the industrialized world and a leading cause of inability of the elderly." | 1.31 | Influence of treatment with Ca(2+) antagonists on cerebral vasculature of spontaneously hypertensive rats. ( Amenta, F; Sabbatini, M; Tomassoni, D, 2001) |
| "Manidipine-treated groups 3 to 5 had significantly less proteinuria than group 2." | 1.29 | Effects of a calcium antagonist, manidipine, on progressive renal injury associated with mild hypertension in remnant kidneys. ( Hishida, A; Kobayashi, S, 1995) |
| " Moreover, chronic administration of manidipine attenuated the rise in MAP in salt-loaded SHR (155 +/- 3 mmHg vs." | 1.29 | Effect of a calcium antagonist on renal hemodynamics in salt-loaded spontaneously hypertensive rats. ( Ando, K; Fujita, T; Shimosawa, T, 1995) |
| "Hydronephrosis was induced by ligation of the left ureter in 8-week-old stroke-prone spontaneously hypertensive rats." | 1.29 | Effects of a calcium antagonist and an angiotensin II receptor antagonist on rat renal arterioles. ( Goto, A; Hayakawa, H; Hirata, Y; Kimura, K; Omata, M; Tojo, A, 1994) |
| " These results indicate that chronic administration of manidipine HCl increases renal blood flow (RBF) by dilating the afferent arterioles and improves glomerular hypertension by dilating the efferent arterioles." | 1.28 | Effects of manidipine hydrochloride on the renal microcirculation in spontaneously hypertensive rats. ( Kimura, K; Matsuoka, H; Sugimoto, T; Tojo, A, 1992) |
| "Treatment with manidipine (3 mg/kg/day) or delapril (30 mg/kg/day) lowered systolic blood pressure (SBP) significantly (p < 0." | 1.28 | Regulation of the gene expression of type-1 angiotensin II receptor in spontaneously hypertensive rats. ( Hiwada, K; Iwata, T; Kitami, Y; Marumoto, K; Okura, T; Wakamiya, R, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.98) | 18.7374 |
| 1990's | 46 (45.54) | 18.2507 |
| 2000's | 42 (41.58) | 29.6817 |
| 2010's | 11 (10.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saiz Satjes, M | 1 |
| Martinez-Martin, FJ | 4 |
| Saiz-Satjes, M | 2 |
| Roca-Cusachs, A | 4 |
| Kohlmann, O | 3 |
| Laurent, S | 3 |
| Schmieder, RE | 3 |
| Wenzel, RR | 3 |
| Fogari, R | 17 |
| Cavalieri, L | 1 |
| Cremonesi, G | 3 |
| Martínez Martín, FJ | 2 |
| Galceran, J | 1 |
| Plana, J | 1 |
| Felip, A | 1 |
| Pou, G | 1 |
| Vila, J | 1 |
| Sobrino, J | 1 |
| Richy, FF | 1 |
| Macias-Batista, A | 1 |
| Comi-Diaz, C | 1 |
| Rodriguez-Rosas, H | 1 |
| Soriano-Perera, P | 1 |
| Pedrianes-Martin, P | 1 |
| Martell-Claros, N | 1 |
| de la Cruz, JJ | 1 |
| Mugellini, A | 14 |
| Circelli, M | 1 |
| Weir, MR | 1 |
| Ruggenenti, P | 1 |
| Lauria, G | 1 |
| Iliev, IP | 1 |
| Fassi, A | 1 |
| Ilieva, AP | 1 |
| Rota, S | 1 |
| Chiurchiu, C | 1 |
| Barlovic, DP | 1 |
| Sghirlanzoni, A | 1 |
| Lombardi, R | 1 |
| Penza, P | 1 |
| Cavaletti, G | 1 |
| Piatti, ML | 1 |
| Frigeni, B | 1 |
| Filipponi, M | 1 |
| Rubis, N | 1 |
| Noris, G | 1 |
| Motterlini, N | 1 |
| Ene-Iordache, B | 1 |
| Gaspari, F | 1 |
| Perna, A | 1 |
| Zaletel, J | 1 |
| Bossi, A | 1 |
| Dodesini, AR | 1 |
| Trevisan, R | 1 |
| Remuzzi, G | 1 |
| Liberopoulos, EN | 1 |
| Moutzouri, E | 1 |
| Rizos, CV | 1 |
| Barkas, F | 1 |
| Liamis, G | 1 |
| Elisaf, MS | 1 |
| Ott, C | 1 |
| Schneider, MP | 1 |
| Raff, U | 1 |
| Ritt, M | 1 |
| Striepe, K | 1 |
| Alberici, M | 2 |
| Bellinghieri, G | 1 |
| Mazzaglia, G | 1 |
| Savica, V | 1 |
| Santoro, D | 1 |
| Preti, P | 8 |
| Zoppi, A | 12 |
| Corradi, L | 6 |
| Fogari, E | 3 |
| Derosa, G | 3 |
| McKeage, K | 1 |
| Scott, LJ | 1 |
| Ueshiba, H | 1 |
| Miyachi, Y | 1 |
| Yamanari, H | 1 |
| Nakamura, K | 1 |
| Kakishita, M | 1 |
| Ohe, T | 1 |
| Tikhonoff, V | 1 |
| Mazza, A | 1 |
| Casiglia, E | 1 |
| Pessina, AC | 2 |
| Dobovisek, J | 1 |
| Planinc, D | 1 |
| Rinaldi, A | 5 |
| Lazzari, P | 5 |
| Luque Otero, M | 1 |
| Martell Claros, N | 1 |
| Destro, M | 1 |
| Vaccarella, A | 1 |
| Celentano, A | 2 |
| Scanferla, F | 1 |
| Toba, H | 1 |
| Nakagawa, Y | 1 |
| Miki, S | 1 |
| Shimizu, T | 1 |
| Yoshimura, A | 1 |
| Inoue, R | 1 |
| Asayama, J | 2 |
| Kobara, M | 1 |
| Nakata, T | 2 |
| Triposkiadis, F | 2 |
| Zanchetti, A | 3 |
| Kahan, T | 1 |
| Ambrosioni, E | 1 |
| McCormack, PL | 1 |
| Keating, GM | 1 |
| Coca, A | 1 |
| Malamani, G | 1 |
| Perrone, T | 1 |
| Otero, ML | 1 |
| Payeras, AC | 1 |
| Sladek, K | 1 |
| Lembo, G | 1 |
| Kobayashi, H | 1 |
| Obara, T | 1 |
| Takahashi, N | 1 |
| Takahashi, T | 1 |
| Igari, Y | 1 |
| Oikawa, T | 1 |
| Saito, S | 1 |
| Ohkubo, T | 1 |
| Imai, Y | 1 |
| Takahashi, M | 2 |
| Kobayashi, S | 1 |
| Hishida, A | 1 |
| Onuki, T | 1 |
| Yoshimoto, T | 2 |
| Naruse, M | 2 |
| Tanabe, A | 2 |
| Naruse, K | 2 |
| Takagi, K | 1 |
| Muraki, T | 2 |
| Itakura, M | 1 |
| Hagiwara, H | 2 |
| Hirose, S | 2 |
| Demura, H | 2 |
| Kimura, K | 2 |
| Tojo, A | 2 |
| Hirata, Y | 1 |
| Hayakawa, H | 1 |
| Goto, A | 1 |
| Omata, M | 1 |
| Sato, K | 2 |
| Kojima, M | 2 |
| Dohi, Y | 2 |
| Lai, YH | 1 |
| Guh, JY | 1 |
| Chen, HC | 1 |
| Hwang, SJ | 1 |
| Tsai, JC | 1 |
| Tsai, JH | 1 |
| Nakashima, K | 1 |
| Shimoda, M | 1 |
| Kuno, N | 1 |
| Takahashi, K | 1 |
| Takabatake, T | 1 |
| Ohta, H | 1 |
| Sasaki, T | 1 |
| Satoh, S | 1 |
| Ohta, K | 1 |
| Ise, T | 1 |
| Kobayashi, K | 1 |
| Nayler, WG | 1 |
| Panagiotopoulos, S | 1 |
| Saruta, T | 2 |
| Suzuki, H | 2 |
| Iimura, O | 1 |
| Shimamoto, K | 1 |
| Shionoya, K | 1 |
| Tanaka, M | 1 |
| Shimosawa, T | 1 |
| Ando, K | 1 |
| Fujita, T | 1 |
| Stella, ML | 1 |
| Grassi, G | 1 |
| Paleari, F | 1 |
| Gamba, P | 1 |
| Mancia, G | 2 |
| Suzuki, S | 1 |
| Ohtomo, M | 1 |
| Satoh, Y | 1 |
| Kawasaki, H | 1 |
| Hirai, M | 1 |
| Hirai, A | 1 |
| Hirai, S | 1 |
| Onoda, M | 1 |
| Hinokio, Y | 1 |
| Akai, H | 1 |
| Toyota, T | 1 |
| Rodicio, JL | 1 |
| Lusardi, P | 3 |
| Poletti, L | 1 |
| Crivaro, M | 1 |
| Perticone, F | 1 |
| Palmieri, V | 1 |
| Oliviero, M | 1 |
| Tammaro, P | 1 |
| Pietropaolo, I | 1 |
| Di Palma Esposito, N | 1 |
| Cloro, C | 1 |
| Cosco, C | 1 |
| Mattioli, PL | 1 |
| De Divitiis, O | 1 |
| Hamada, Y | 1 |
| Niisato, E | 1 |
| Otori, T | 1 |
| Chikugo, TA | 1 |
| Ohta, Y | 3 |
| Suzuki, T | 3 |
| Okamoto, K | 1 |
| Akagashi, K | 1 |
| Itoh, N | 1 |
| Kumamoto, Y | 1 |
| Tsukamoto, T | 1 |
| Tomiyama, H | 1 |
| Kimura, Y | 3 |
| Sakuma, Y | 1 |
| Shiojima, K | 1 |
| Yamamoto, A | 1 |
| Saito, I | 1 |
| Ishikawa, Y | 1 |
| Yoshida, H | 1 |
| Morita, S | 1 |
| Doba, N | 1 |
| Chiba, A | 1 |
| Nakanishi, H | 1 |
| Chichibu, S | 1 |
| Miyagawa, K | 1 |
| Tanabe, M | 1 |
| Iwata, H | 1 |
| Kinoshita, M | 1 |
| Sumiya, M | 1 |
| Saima, S | 1 |
| Shiba, T | 1 |
| Inoue, M | 1 |
| Tada, H | 1 |
| Hayashi, Y | 1 |
| Okuda, Y | 1 |
| Fujita, R | 1 |
| Makino, F | 1 |
| Takahasi, C | 1 |
| Kageyama, S | 1 |
| Kitamura, S | 1 |
| Iwamoto, Y | 1 |
| Ogihara, T | 3 |
| Omboni, S | 2 |
| Agabiti-Rosei, E | 1 |
| Casati, R | 1 |
| Leonetti, G | 1 |
| Montemurro, G | 1 |
| Nami, R | 1 |
| Pirrelli, A | 1 |
| Malalamani, GD | 1 |
| Sabbatini, M | 2 |
| Tomassoni, D | 2 |
| Amenta, F | 2 |
| Tanaka, H | 1 |
| Teramoto, S | 1 |
| Oashi, K | 1 |
| Saikai, T | 1 |
| Tanaka, S | 1 |
| Suzuki, K | 2 |
| Hashimoto, M | 1 |
| Abe, S | 1 |
| La Commare, P | 1 |
| De Cesaris, R | 1 |
| Palatini, P | 1 |
| Cheer, SM | 1 |
| McClellan, K | 1 |
| Ribeiro, AB | 1 |
| Ikawa, K | 1 |
| Ikawa, M | 1 |
| Shimauchi, H | 1 |
| Iwakura, M | 1 |
| Sakamoto, S | 1 |
| Matsuoka, H | 2 |
| Sugimoto, T | 2 |
| Maki, M | 1 |
| Kawamura, H | 1 |
| Hara, K | 1 |
| Mitsubayashi, H | 1 |
| Itou, S | 1 |
| Usui, W | 1 |
| Yasugi, T | 1 |
| Murakami, K | 1 |
| Kimura, G | 1 |
| Imanishi, M | 1 |
| Sanai, T | 1 |
| Kawano, Y | 2 |
| Kojima, S | 1 |
| Yoshida, K | 1 |
| Abe, H | 1 |
| Ashida, T | 1 |
| Yoshimi, H | 1 |
| Mizuno, K | 1 |
| Haga, H | 1 |
| Watanabe, Y | 1 |
| Fukuchi, S | 1 |
| Kitami, Y | 2 |
| Okura, T | 2 |
| Wakamiya, R | 2 |
| Marumoto, K | 2 |
| Iwata, T | 2 |
| Hiwada, K | 2 |
| Hirakata, H | 1 |
| Iino, K | 1 |
| Ishida, I | 1 |
| Kashiwagi, M | 1 |
| Yoshinari, M | 1 |
| Okuda, S | 1 |
| Fujita, S | 1 |
| Fujishima, M | 1 |
| Atarashi, K | 1 |
| Takagi, M | 1 |
| Minami, M | 1 |
| Nakagawa, M | 2 |
| Ishikawa, H | 1 |
| Mikami, H | 2 |
| Takeda, K | 2 |
| Nonaka, H | 1 |
| Nagano, M | 2 |
| Sasaki, S | 2 |
| Kagoshima, T | 1 |
| Higashimori, K | 1 |
| Fujiwara, Y | 1 |
| Ochi, S | 1 |
| Izumi, M | 1 |
| Yokoyama, K | 1 |
| Arai, M | 1 |
| Ando, A | 1 |
| Nagaoka, A | 2 |
| Kamada, T | 1 |
| Ueda, N | 1 |
| Morishita, R | 1 |
| Higaki, J | 1 |
| Nakamura, F | 1 |
| Tomita, N | 1 |
| Yu, H | 1 |
| Kuwabara, T | 1 |
| Itoh, H | 1 |
| Yamahara, Y | 1 |
| Takesako, T | 1 |
| Tanabe, S | 1 |
| Takishita, S | 2 |
| Muratani, H | 2 |
| Kawazoe, N | 2 |
| Tozawa, M | 2 |
| Fukiyama, K | 2 |
| Ikenaga, H | 1 |
| Nara, Y | 1 |
| Ikeda, K | 1 |
| Yamori, Y | 1 |
| Iwata, A | 1 |
| Tochikubo, O | 1 |
| Minamisawa, K | 1 |
| Miyakawa, Y | 1 |
| Ishii, M | 1 |
| Nakamura, T | 1 |
| Honma, H | 1 |
| Kohno, I | 1 |
| Tsuruta, I | 1 |
| Ishii, H | 1 |
| Tamura, K | 1 |
| Morimoto, S | 1 |
| Ohyama, T | 1 |
| Hisaki, K | 1 |
| Matsumura, Y | 1 |
| Kakihana, M | 1 |
| Suno, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Manidipine Versus Amlodipine in Patients With Hypertension: Effects on Peripheral Edema Evaluated by Bioimpedance Analysis[NCT03106597] | Phase 4 | 46 participants (Actual) | Interventional | 2015-08-20 | Terminated (stopped due to Difficulty in enrolling subjects) | ||
| A Multicenter, Randomized, Prospective, Double-blind Study to Evaluate the Nephroprotective Effect of Delapril Alone or Combined With Manidipine in Patients With Type 2 Diabetes[NCT00157586] | Phase 3 | 342 participants | Interventional | 2002-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 reviews available for manidipine and Hypertension
| Article | Year |
|---|---|
Treatment of hypertensive patients with diabetes: beyond blood pressure control and focus on manidipine.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus; Di | 2016 |
Metabolic effects of manidipine.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Clinical Trials as Topic; Dihydropyridines; Endot | 2009 |
Manidipine treatment in patients with albuminuria not sufficiently reduced with renin-angiotensin system blockers.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Clinical Trial | 2010 |
Efficacy and safety profiles of manidipine compared with amlodipine: a meta-analysis of head-to-head trials.
Topics: Adult; Amlodipine; Ankle; Antihypertensive Agents; Blood Pressure; Dihydropyridines; Edema; Humans; | 2011 |
Combination delapril/manidipine as antihypertensive therapy in high-risk patients.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Diabetes Comp | 2011 |
Manidipine: a review of its use in the management of hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dihydropy | 2004 |
Fixed combination of manidipine and delapril in the treatment of mild to moderate essential hypertension: evaluation by 24-hour ambulatory blood pressure monitoring.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Bloo | 2005 |
Antihypertensive effect of manidipine.
Topics: Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channe | 2005 |
Renal protection in hypertensive patients: selection of antihypertensive therapy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
Manidipine plus delapril in patients with Type 2 diabetes and hypertension: reducing cardiovascular risk and end-organ damage.
Topics: Blood Pressure Determination; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropat | 2007 |
Manidipine-delapril combination in the management of hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel B | 2007 |
[Calcium channel-blockers for managing metabolic syndrome-associated hypertension. Trials with manidipine].
Topics: Albuminuria; Calcium Channel Blockers; Dihydropyridines; Endothelium, Vascular; Humans; Hypertension | 2007 |
[[Antihypertensive therapy and organ protection].
Topics: Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Circadian Rhythm; Diasto | 1996 |
Renal effects of calcium antagonists with special reference to manidipine hydrochloride.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Female; Glomerular Filtration R | 1996 |
Manidipine: a review of its use in hypertension.
Topics: Aged; Animals; Antihypertensive Agents; Diabetes Complications; Dihydropyridines; Hemodynamics; Huma | 2001 |
45 trials available for manidipine and Hypertension
| Article | Year |
|---|---|
Factors associated with the reduction of albumin excretion in diabetic hypertensive patients: differential effect of manidipine versus amlodipine.
Topics: Adult; Aged; Albumins; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Me | 2017 |
Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study.
Topics: Adult; Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convertin | 2008 |
Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Ty | 2009 |
Manidipine in hypertensive patients with metabolic syndrome: the MARIMBA study.
Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Antihypertensive Agents; Blood | 2009 |
Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimid | 2011 |
Manidipine for hypertension not controlled by dual therapy in patients with diabetes mellitus: a non-comparative, open-label study.
Topics: Aged; Antihypertensive Agents; Diabetes Complications; Dihydropyridines; Drug Therapy, Combination; | 2011 |
Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Body Mass Index; Calcium Chann | 2011 |
Effects of manidipine plus rosuvastatin versus olmesartan plus rosuvastatin on markers of insulin resistance in patients with impaired fasting glucose, hypertension, and mixed dyslipidemia.
Topics: Aged; Blood Glucose; Dihydropyridines; Drug Therapy, Combination; Dyslipidemias; Endpoint Determinat | 2013 |
Effects of manidipine vs. amlodipine on intrarenal haemodynamics in patients with arterial hypertension.
Topics: Adult; Aged; Albuminuria; Amlodipine; Creatinine; Dihydropyridines; Double-Blind Method; Female; Hem | 2013 |
Effects of manidipine and nifedipine on blood pressure and renal function in patients with chronic renal failure: a multicenter randomized controlled trial.
Topics: Adult; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Female; Humans; Hypertension; Kid | 2003 |
Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus.
Topics: Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Dihydropyridine | 2004 |
Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients.
Topics: Aged; Amlodipine; Analysis of Variance; Body Mass Index; Calcium Channel Blockers; Dehydroepiandrost | 2004 |
Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension: results of a randomized trial.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Dihydro | 2004 |
Effect of manidipine as compared to atenolol on platelet aggregation in elderly patients with isolated systolic hypertension and type II diabetes mellitus.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Atenolol; Cross-Over Studies; Diabetes Mellitus, Type | 2005 |
Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Calcium Channel Blockers; D | 2005 |
Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria.
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Diabetes Mell | 2005 |
Fixed combination of manidipine and delapril in the treatment of mild to moderate essential hypertension: evaluation by 24-hour ambulatory blood pressure monitoring.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Bloo | 2005 |
Effect on the development of ankle edema of adding delapril to manidipine in patients with mild to moderate essential hypertension: a three-way crossover study.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Ankle; Antihypertensive Agents; Calcium Chann | 2007 |
Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular | 2007 |
Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2007 |
Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 2008 |
Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diabetes Co | 2008 |
Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2008 |
Effects of manidipine hydrochloride on blood pressure in hypertensive patients--a comparison with nifedipine retard.
Topics: Adult; Aged; Blood Pressure; Dihydropyridines; Female; Humans; Hypertension; Male; Middle Aged; Nife | 1993 |
Efficacy of manidipine in the treatment of hypertension with renal impairment: a multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Antihypertensive Agents; Blood Urea Nitrogen; Calcium C | 1993 |
Evaluation by 24-hour ambulatory blood pressure monitoring of efficacy of manidipine hydrochloride 10, 20 or 40 mg once daily as compared to placebo in treating mild to moderate essential hypertension: a double-blind, randomized, parallel group, placebo-c
Topics: Adult; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dihydropyridines; Double-Blind Method; | 1996 |
Efficacy and tolerability of manidipine hydrochloride in the long-term treatment of mild-moderate hypertension. Manidipine Efficacy in Long-Term Treatment Group.
Topics: Antihypertensive Agents; Blood Pressure; Dihydropyridines; Female; Humans; Hypertension; Male; Middl | 1996 |
Anti-hypertensive effect of manidipine: 24 hours monitoring evaluation and Doppler-echocardiographic remarks.
Topics: Adult; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Dihydr | 1996 |
Effects of an ACE inhibitor and a calcium channel blocker on cardiovascular autonomic nervous system and carotid distensibility in patients with mild to moderate hypertension.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Autonomic Nervous System; Baroreflex; Calcium Channe | 1998 |
Effect of low-dose manidipine on ambulatory blood pressure in very elderly hypertensives.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat | 1999 |
Delapril versus manidipine in hypertensive therapy to halt the type-2-diabetes-mellitus-associated nephropathy.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calc | 2000 |
Practitioner's Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (The PATE-Hypertension Study) in Japan.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers; Delayed-Ac | 2000 |
Antihypertensive efficacy of manidipine and enalapril in hypertensive diabetic patients.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Blood | 2000 |
Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydrop | 2000 |
Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma.
Topics: Adult; Aged; Antihypertensive Agents; Asthma; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Br | 2001 |
Efficacy, tolerability, and impact on quality of life of long-term treatment with manidipine or amlodipine in patients with essential hypertension.
Topics: Adult; Aged; Amlodipine; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Chi-Square D | 2001 |
[Manidipine in the treatment of stage I and II essential hypertension patients with overweight or android obesity. A Brazilian multicentre study of efficacy, tolerability and metabolic effects].
Topics: Adult; Antihypertensive Agents; Blood Glucose; Brazil; Dihydropyridines; Female; Humans; Hypertensio | 2001 |
The effect of manidipine on renal hemodynamics in essential hypertensive patients: responses to acute stress.
Topics: Acute Disease; Adult; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Female; Hemodynami | 1992 |
Effect of manidipine, a new calcium antagonist, on intrarenal hemodynamics in essential hypertension.
Topics: Blood Pressure; Blood Proteins; Calcium Channel Blockers; Dihydropyridines; Female; Glomerular Filtr | 1992 |
Clinical evaluation of the efficacy and safety of manidipine in hypertensive patients with renal disorders.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Blood Urea Nitrogen; Calcium Channel Blockers; Creat | 1992 |
Effects of a new calcium antagonist, manidipine, on the renal hemodynamics and the vasoactive humoral factors in patients with diabetes mellitus.
Topics: Adult; Angiotensin II; Atrial Natriuretic Factor; Blood Glucose; Blood Pressure; Calcium Channel Blo | 1992 |
Effects of manidipine and delapril on glucose and lipid metabolism in hypertensive patients with non-insulin-dependent diabetes mellitus.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Calcium Channel Block | 1992 |
Effect of manidipine, a novel calcium channel blocker, on quality of life in hypertensive patients.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Humans; | 1992 |
A study of the effects of manidipine on the diurnal variation of arterial pressure and hemodynamics in patients with essential hypertension.
Topics: Adult; Aged; Blood Pressure; Calcium Channel Blockers; Circadian Rhythm; Diastole; Dihydropyridines; | 1992 |
Efficacy of manidipine on circadian blood pressure in essential hypertension.
Topics: Adult; Aged; Blood Pressure; Blood Pressure Monitors; Calcium Channel Blockers; Circadian Rhythm; Di | 1992 |
42 other studies available for manidipine and Hypertension
| Article | Year |
|---|---|
Optimal treatment strategies for patients with hypertension and diabetes: are effects on metabolism important?
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dihydropyridines; Female; Humans; Hypertension; Indans; Ma | 2011 |
Effects of cyclooxygenase inhibition on endothelial function in hypertensive patients treated with angiotensin-converting enzyme inhibitors.
Topics: Administration, Sublingual; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspir | 2004 |
Role of manidipine in the management of patients with hypertension.
Topics: Adult; Aged; Animals; Biological Availability; Blood Pressure Monitoring, Ambulatory; Dihydropyridin | 2004 |
Calcium channel blockades exhibit anti-inflammatory and antioxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the N(G)-nitro-L-arginine methyl ester-induced hypertensive rat aorta
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents; Antihyperte | 2005 |
Closing remarks: current position of calcium channel antagonists in hypertension--the role of manidipine.
Topics: Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Humans; Hypertension; Nitrobenzenes; Pip | 2005 |
Delapril/manidipine: viewpoints.
Topics: Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Bloc | 2006 |
Delapril/manidipine.
Topics: Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Bloc | 2006 |
[Evaluation of efficacy and safety of manidipine hydrochloride among essential hypertensive patients: Substitution from branded product (Calslot) to Generic Product (Manidip)].
Topics: Aged; Aged, 80 and over; Calcium Channel Blockers; Dihydropyridines; Drug Administration Schedule; D | 2007 |
Effects of a calcium antagonist, manidipine, on progressive renal injury associated with mild hypertension in remnant kidneys.
Topics: Animals; Calcium Channel Blockers; Dihydropyridines; Dose-Response Relationship, Drug; Hypertension; | 1995 |
Effects of a calcium channel blocker, manidipine hydrochloride, on the regulatory mechanism of glomerular capillary pressure in SHR.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Capillaries; Dihydropyridines; Feedback; Hyperten | 1995 |
Angiotensin converting enzyme inhibitor but not calcium blocker down-regulates gene expression of vascular natriuretic peptide receptor in hypertensive rats.
Topics: Animals; Aorta; Blood Pressure; Dihydropyridines; Down-Regulation; Hypertension; Indans; Male; Nitro | 1994 |
Effects of a calcium antagonist and an angiotensin II receptor antagonist on rat renal arterioles.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arterioles; Benzimidazoles; Biph | 1994 |
Antihypertensive treatment in patients with a history of accelerated malignant hypertension, with special reference to clinical decision-making in changing treatment.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Dihydropyridines; Drug Therapy, Combination; Female; | 1994 |
Clinical Pharmacology of Manidipine for the Treatment of Hypertension: Importance of Renal and Additional Organ Protective Properties. Proceedings of a symposium. Madrid, Spain, June 13, 1992.
Topics: Animals; Antihypertensive Agents; Calcium Channel Blockers; Dihydropyridines; Humans; Hypertension; | 1993 |
Temporary symptom worsening caused by manidipine hydrochloride in two patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Antiparkinson Agents; Dihydropyridines; Drug Thera | 1994 |
Renal effects of manidipine hydrochloride. A new calcium antagonist in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Fe | 1993 |
The antiatherosclerotic effect of the calcium antagonists and their implications in hypertension.
Topics: Animals; Aorta, Abdominal; Aorta, Thoracic; Arteriosclerosis; Calcium; Calcium Channel Blockers; Cho | 1993 |
Efficacy and mode of action of manidipine: a new calcium antagonist.
Topics: Adult; Aldosterone; Calcium; Calcium Channel Blockers; Dihydropyridines; Diuresis; Female; Hemodynam | 1993 |
Angiotensin II-dependent down-regulation of vascular natriuretic peptide type C receptor gene expression in hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Calci | 1996 |
Effect of a calcium antagonist on renal hemodynamics in salt-loaded spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Hemody | 1995 |
Effect of manidipine and delapril on insulin sensitivity in type 2 diabetic patients with essential hypertension.
Topics: Antihypertensive Agents; Blood Glucose; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabeti | 1996 |
Ocular fundus changes in malignant or precocious stroke-prone spontaneously hypertensive rats after administration of antihypertensive drugs.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Arterioles; Blood Pressu | 1995 |
Protective effects of manidipine on spermatogenesis in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Cerebrovascular Disorders; Cytosol; Dihydropyridi | 1995 |
Changes in the gastric vascular network of malignant stroke-prone spontaneously hypertensive rats (M-SHRSP) after administration of the calcium antagonist manidipine.
Topics: Animals; Antihypertensive Agents; Arteries; Blood Pressure; Calcium Channel Blockers; Capillaries; D | 1998 |
Acute antihypertensive effects of calcium channel blockers are not affected by calcium supplementation in patients with essential hypertension.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; Calcium; Calcium Channel Block | 1998 |
Manidipine hydrochloride-induced chyloperitoneum in a patient with systemic lupus erythematosus.
Topics: Adult; Calcium Channel Blockers; Chylous Ascites; Dihydropyridines; Female; Humans; Hypertension; Lu | 1999 |
Influence of treatment with Ca(2+) antagonists on cerebral vasculature of spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Brain; Calcium Channel Blockers; Cerebrovascular C | 2001 |
Hypertensive brain damage: comparative evaluation of protective effect of treatment with dihydropyridine derivatives in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Brain; Brain Injuries; Calcium Channel Blockers; D | 2001 |
Treatment of gingival overgrowth induced by manidipine administration. A case report.
Topics: Adult; Antihypertensive Agents; Calcium Channel Blockers; Dental Plaque Index; Dental Scaling; Dentu | 2002 |
Effects of manidipine hydrochloride on the renal microcirculation in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Calcium Channel Blockers; Dihydropyridines; Hypertension; Kidney G | 1992 |
Regulation of the gene expression of type-1 angiotensin II receptor in spontaneously hypertensive rats.
Topics: Adrenal Glands; Angiotensin-Converting Enzyme Inhibitors; Animals; Autoradiography; Base Sequence; B | 1992 |
Mesangial cell growth in genetically hypertensive rats and effect of calcium antagonists upon this growth.
Topics: Animals; Calcium Channel Blockers; Cell Division; Cells, Cultured; Dihydropyridines; Dose-Response R | 1992 |
Regression of hypertension-induced vascular hypertrophy by an ACE inhibitor and calcium antagonist in the spontaneously hypertensive rat.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Aorta, A | 1992 |
Effect of manidipine on cardiac hypertrophy and coronary circulation in DOCA/salt hypertensive rats.
Topics: Aldosterone; Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Coronary Circulation; C | 1992 |
Nephroprotective actions and other tissue protective effects of manidipine in the management of hypertension.
Topics: Animals; Antihypertensive Agents; Dihydropyridines; Humans; Hypertension; Kidney; Kidney Diseases; N | 1992 |
Acute effects of manidipine on renal blood flow and sympathetic nerve activity in conscious, spontaneously hypertensive rats.
Topics: Air Pressure; Animals; Blood Pressure; Consciousness; Dihydropyridines; Heart Rate; Hypertension; Ki | 1992 |
Renal and extra-renal renin gene expression in spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Autoradiography; Base Sequence; Blood Pressure; B | 1992 |
Renal vascular responses in spontaneously hypertensive rats chronically treated with manidipine.
Topics: Air Pressure; Angiotensin II; Animals; Blood Pressure; Body Weight; Calcium Channel Blockers; Dihydr | 1992 |
Effects of manidipine on blood pressure and renal function in salt-loaded, spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Body Weight; Calcium Channel Blockers; Dihydropyridines; Glomerular Filtrat | 1992 |
Preventive effect of manidipine on severe hypertension and proteinuria induced by the inhibition of endothelial-derived relaxation factor formation in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Arginine; Blood Pressure; Calcium Channel Blockers; Cerebrovascular Disorders; Dihydropyrid | 1992 |
Effects of CV-4093, a new dihydropyridine calcium channel blocker, on renal hemodynamics and function in stroke-prone spontaneously hypertensive rats (SHRSP).
Topics: Animals; Body Weight; Calcium Channel Blockers; Cerebrovascular Disorders; Dihydropyridines; Hemodyn | 1989 |
Antihypertensive effect of CV-4093.2HCl, a new calcium antagonist, in three rat models of hypertension.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Hypert | 1988 |